By: ICN Bureau
Last updated : January 27, 2022 5:45 pm
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India.
Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.
Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the pandemic. The company is ready to launch the product this week, so as to make the product available to suffering patients across India.
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of Rs. 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in new drug development, etc.
Natco family currently consists of around 5,000 employees and consistently ranks among fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in pharmaceutical R&D.